Literature DB >> 6974823

Acetylcholine receptor antibodies in myasthenia gravis.

P Kornfeld, J Nall, H Smith, T W Mittag, A N Bender, E P Ambinder, S H Horowitz, A E Papatestas, H Gross, G Genkins.   

Abstract

A multivariate statistical analysis of levels of serum acetylcholine receptor antibody (AChR Ab) obtained from 197 patients with various clinical forms of myasthenia gravis (MG) was performed. Elevated AChR Ab levels are specific for MG, but normal AChR Ab levels do not rule out MG. Patients in remission or with purely ocular MG had the lowest incidence of elevation of serum AChR Ab levels, while patients with generalized, severe MG, particularly in the presence of thymoma, tended to have the greatest antibody elevations. Corticosteroids depressed AChR Ab levels, but thymectomy did not exert a consistent effect on antibody levels within a 24- to 30-month postoperative period. The relatively low 55% positivity of antibody elevations in all 197 patients probably reflects the use of heterologous (rat) AChR.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6974823     DOI: 10.1002/mus.880040510

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

1.  Circulating CD4+CD8+ cells in myasthenia gravis: supplementary immunological parameter for long-term prognosis.

Authors:  M Matsui; H Fukuyama; I Akiguchi; M Kameyama
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

Review 2.  The role of surgery of the thymus for myasthenia gravis.

Authors:  C L Robinson
Journal:  Ann R Coll Surg Engl       Date:  1983-05       Impact factor: 1.891

3.  Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.

Authors:  A Vincent; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

4.  Clinical implementation of anti-acetylcholine receptor antibodies.

Authors:  F E Somnier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.